Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event
- Live moderated video webcast with members of management to discuss its ongoing Phase 1/2 study of core technology in development, Annamycin for the treatment of Acute Myeloid Leukemia, on Wednesday, September 28 at 11:00 AM ET HOUSTON, Sept. 23, 2022 -- Moleculin...
Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
HOUSTON, Sept. 8, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of...
Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 7, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp,...
Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
- Glioblastoma is the most aggressive malignant primary brain tumor with serious unmet medical need HOUSTON, Sept. 6, 2022 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...
Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
- Preliminary results of third cohort in the first-in-human Phase 1a allows Company to proceed to next single ascending dose (SAD) of 64 mg/kg dose and the first multiple ascending dose (MAD) cohort to commence with 32 mg/kg dose of WP1122 - HOUSTON, Aug. 19, 2022 --...
Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update
- Continued advancement across clinical and preclinical programs; on track with multiple milestones and key data readouts expected through the second half of 2022 - Company has sufficient capital to fund operations beyond mid-2024 HOUSTON, Aug. 15, 2022 -- Moleculin...
Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
- Preliminary Phase 1b data demonstrated clinical activity, defined as stable disease or better - Company determines RP2D to be 360 mg/m2 and will begin Phase 2 recruitment - Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of...
Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
- Preliminary results of second cohort in the first-in-human Phase 1a allow Company to proceed to 32 mg/kg dose of WP1122 in third cohort toward establishing maximum tolerated dose (MTD) -- Multiple ascending dose (MAD) cohort to commence after completion of at least...
Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
- Preliminary results of first cohort in the first-in-human Phase 1a allows Company to proceed to 16 mg/kg dose of WP1122 in second cohort toward establishing maximum tolerated dose (MTD) - - Multiple ascending dose (MAD) cohort to commence after completion of at...
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
- Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose - - Multiple ascending dose (MAD) cohort to commence after completion of at least 3 SAD dosing cohorts in which...